HomeCompareGNRRF vs BTI

GNRRF vs BTI: Dividend Comparison 2026

GNRRF yields 43.96% · BTI yields 5.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GNRRF wins by $249.2K in total portfolio value
10 years
GNRRF
GNRRF
● Live price
43.96%
Share price
$4.55
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$287.0K
Annual income
$52,411.25
Full GNRRF calculator →
BTI
BTI
● Live price
5.40%
Share price
$58.26
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.8K
Annual income
$2,802.29
Full BTI calculator →

Portfolio growth — GNRRF vs BTI

📍 GNRRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGNRRFBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GNRRF + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GNRRF pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GNRRF
Annual income on $10K today (after 15% tax)
$3,736.26/yr
After 10yr DRIP, annual income (after tax)
$44,549.56/yr
BTI
Annual income on $10K today (after 15% tax)
$459.05/yr
After 10yr DRIP, annual income (after tax)
$2,381.95/yr
At 15% tax rate, GNRRF beats the other by $42,167.62/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GNRRF + BTI for your $10,000?

GNRRF: 50%BTI: 50%
100% BTI50/50100% GNRRF
Portfolio after 10yr
$162.4K
Annual income
$27,606.77/yr
Blended yield
17.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

GNRRF
No analyst data
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.3% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GNRRF buys
0
BTI buys
0
No recent congressional trades found for GNRRF or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGNRRFBTI
Forward yield43.96%5.40%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$287.0K$37.8K
Annual income after 10y$52,411.25$2,802.29
Total dividends collected$221.7K$14.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: GNRRF vs BTI ($10,000, DRIP)

YearGNRRF PortfolioGNRRF Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$15,096$4,395.60$11,301$601.08+$3.8KGNRRF
2$22,354$6,201.34$12,799$706.58+$9.6KGNRRF
3$32,501$8,582.21$14,527$832.38+$18.0KGNRRF
4$46,437$11,661.61$16,527$982.75+$29.9KGNRRF
5$65,260$15,572.20$18,846$1,162.95+$46.4KGNRRF
6$90,281$20,452.54$21,545$1,379.49+$68.7KGNRRF
7$123,043$26,443.04$24,694$1,640.41+$98.3KGNRRF
8$165,338$33,681.45$28,378$1,955.69+$137.0KGNRRF
9$219,210$42,298.12$32,702$2,337.79+$186.5KGNRRF
10$286,966$52,411.25$37,794$2,802.29+$249.2KGNRRF

GNRRF vs BTI: Complete Analysis 2026

GNRRFStock

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic centers to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.

Full GNRRF Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this GNRRF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GNRRF vs SCHDGNRRF vs JEPIGNRRF vs OGNRRF vs KOGNRRF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.